X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs BIOCON LTD - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD BIOCON LTD MERCK LTD/
BIOCON LTD
 
P/E (TTM) x 47.6 81.6 58.4% View Chart
P/BV x 7.2 6.9 104.0% View Chart
Dividend Yield % 0.4 0.2 234.8%  

Financials

 MERCK LTD   BIOCON LTD
EQUITY SHARE DATA
    MERCK LTD
Dec-16
BIOCON LTD
Mar-18
MERCK LTD/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,0601,188 89.2%   
Low Rs623305 204.3%   
Sales per share (Unadj.) Rs632.468.7 920.3%  
Earnings per share (Unadj.) Rs45.77.6 605.4%  
Cash flow per share (Unadj.) Rs62.314.0 446.1%  
Dividends per share (Unadj.) Rs11.001.00 1,100.0%  
Dividend yield (eoy) %1.30.1 975.8%  
Book value per share (Unadj.) Rs388.886.3 450.3%  
Shares outstanding (eoy) m16.60600.00 2.8%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x1.310.9 12.2%   
Avg P/E ratio x18.498.9 18.6%  
P/CF ratio (eoy) x13.553.4 25.3%  
Price / Book Value ratio x2.28.6 25.0%  
Dividend payout %24.113.2 181.7%   
Avg Mkt Cap Rs m13,969447,900 3.1%   
No. of employees `0001.66.1 25.7%   
Total wages/salary Rs m1,4879,311 16.0%   
Avg. sales/employee Rs Th6,631.96,705.8 98.9%   
Avg. wages/employee Rs Th939.21,514.2 62.0%   
Avg. net profit/employee Rs Th479.4736.9 65.1%   
INCOME DATA
Net Sales Rs m10,49841,234 25.5%  
Other income Rs m2422,062 11.8%   
Total revenues Rs m10,74143,296 24.8%   
Gross profit Rs m1,1358,291 13.7%  
Depreciation Rs m2763,851 7.2%   
Interest Rs m0615 0.0%   
Profit before tax Rs m1,1025,887 18.7%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3431,569 21.9%   
Profit after tax Rs m7594,531 16.7%  
Gross profit margin %10.820.1 53.8%  
Effective tax rate %31.126.7 116.9%   
Net profit margin %7.211.0 65.8%  
BALANCE SHEET DATA
Current assets Rs m6,41041,486 15.4%   
Current liabilities Rs m8,82821,413 41.2%   
Net working cap to sales %-23.048.7 -47.3%  
Current ratio x0.71.9 37.5%  
Inventory Days Days5864 90.2%  
Debtors Days Days3894 40.8%  
Net fixed assets Rs m1,40650,661 2.8%   
Share capital Rs m1663,000 5.5%   
"Free" reserves Rs m6,28648,808 12.9%   
Net worth Rs m6,45551,808 12.5%   
Long term debt Rs m017,898 0.0%   
Total assets Rs m8,82899,897 8.8%  
Interest coverage xNM10.6-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.20.4 288.1%   
Return on assets %8.65.2 166.9%  
Return on equity %11.88.7 134.4%  
Return on capital %17.19.6 177.3%  
Exports to sales %8.30-   
Imports to sales %21.00-   
Exports (fob) Rs m869NA-   
Imports (cif) Rs m2,209NA-   
Fx inflow Rs m95912,058 8.0%   
Fx outflow Rs m2,6127,348 35.5%   
Net fx Rs m-1,6534,710 -35.1%   
CASH FLOW
From Operations Rs m1,0706,621 16.2%  
From Investments Rs m-750-6,840 11.0%  
From Financial Activity Rs m-150-2,397 6.2%  
Net Cashflow Rs m171-2,612 -6.5%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 51.8 20.6 251.5%  
Indian inst/Mut Fund % 18.2 8.4 216.7%  
FIIs % 1.0 10.7 9.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 19.9 146.2%  
Shareholders   28,591 109,995 26.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   J.B.CHEMICALS  ALEMBIC LTD  STERLING BIOTECH  CADILA HEALTHCARE  JUBILANT LIFE SCIENCES  

Compare MERCK LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Depreciating Rupee; IPO Buzz and Top Cues in Focus Today(Pre-Open)

Indian share markets ended lower yesterday with banking stocks and metal stocks leading the losses. At the closing bell, the BSE Sensex ended down by 188 points (0.5%).

Related Views on News

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Aug 16, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD - SHASUN PHARMA COMPARISON

COMPARE MERCK LTD WITH

MARKET STATS